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Abstract 
Lactate transport is mediated in most tissues by H+-monocarboxylate--cotransporters (MCTs). We have cloned and sequenced the 
lactate transporter f om Ehrlich Lettr~ tumour cells by using the polymerase chain reaction (PCR) to amplify MCTl-related sequence 
from cDNA. The sequence is 93% and 87% identical to MCT1 from Chinese hamster and human respectively and so represents mouse 
MCT1. Most differences between MCTI from Chinese hamster and mouse are conservative substitutions, located in hydrophilic parts of 
the molecule. Specific antipeptide antibodies confirm the presence of MCTI protein in membranes from Ehrlich Lettr~ tumour cells. One 
difference between the mouse and Chinese hamster MCTI is the absence of a predicted external consensus equence for N-linked 
glycosylation i the mouse sequence. Using N-glycanase-F treatment and an in vitro translation system, we provide evidence that this 
glycosylation site is not actually utilised in Chinese hamster MCT1. These results are discussed in relation to current understanding of the 
roles of glycosylation of membrane proteins. 
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1. Introduction 
The majority of mammalian cells require lactic acid to 
be transported across the plasma membrane, either as an 
end product of glycolysis that must leave the cell, or as a 
substrate that must enter the cell for respiration or gluco- 
neogenesis. This transport process is known to be mediated 
by a family of monocarboxylate transporters (MCT) all of 
which catalyse the H+/lactate - cotransport, but with dif- 
fering substrate and inhibitor specificities and tissue distri- 
bution [1]. Two of these transporter isoforms have now 
been cloned and sequenced; MCTl from Chinese hamster 
ovary (CHO) cells [2] and MCT2 from Syrian hamster 
liver [3]. These proteins, which are 60% identical, are 
predicted to possess 12 transmembrane (TM) domains and 
Abbreviations: MCT, monocarboxylate transporter; TM, trausmem- 
brane domain; CHO, Chinese hamster ovary; BzNLT, benzoyl-Asn-Leu- 
Thr-N-methylamide. 
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form part of a new family of membrane transporters. The 
best characterised MCT is that found in the erythrocyte 
plasma membrane which we have partially purified [4] and 
whose N-terminal sequence suggests is identical to MCT1 
[51. 
Tumour cells often rely on glycolysis for their ATP 
production and thus the efflux of lactic acid from such 
cells is essential for their well-being. If it were possible to 
inhibit their lactate transport mechanism selectively, it 
might be a suitable strategy for chemotherapy. For this 
purpose we have performed extensive studies on the sub- 
strate and inhibitor specificity of the lactate transporter of 
Ehrlich Lettr~ tumour cells using the intracellular pH 
sensitive fluorescent indicator BCECF [6]. Our data 
strongly implied that these tumour cells possess a lactate 
carrier kinetically indistinguishable from MCTI. However, 
to confirm that MCT1 is responsible we have cloned and 
sequenced the carrier using the polymerase chain reaction 
(PCR) to amplify MCTl-related sequence from cDNA 
prepared from these tumour cells. We have obtained a 
sequence that is 93% identica] to CHO MCT1 which we 
believe to correspond to mouse MCT1, and used specific 
158 L. Carpenter tal. / Biochimica et Biophysica Acta 1279 (1996) 157-163 
antipeptide antibodies to confirm the presence of MCT1 in 
the plasma membranes of Ehrlich Lettr~ tumour cells. A 
notable difference between the mouse and Chinese hamster 
MCT1 is the absence of a putative xternal N-glycosyla- 
tion site in the mouse sequence. We provide evidence that 
this glycosylation site is not actually used in Chinese 
hamster MCT1. 
2. Materials and methods 
2.1. Materials 
Chinese hamsters were obtained from a local breeder. 
Trizol Reagent was obtained from Gibco BRL, Life Tech- 
nologies, Renfrewshire, UK. The reverse transcriptase 
cDNA synthesis kit, TNT T7/T3 Coupled Reticulocyte 
Lysate (rabbit) cell free translation system, and dog pan- 
creatic microsomes were from Promega (Southampton, 
UK) and used according to the suppliers' instructions. Taq 
polymerase was from Boehringer-Mannheim UK (Lewes, 
East Sussex), and the restriction enzymes and general 
molecular biology reagents were either from Boehringer, 
Gibco or Pharmacia (Knowhill, Milton Keynes, UK). The 
QIAquick spin PCR purification kit was obtained from 
Qiagen (Dorking, Surrey, UK). [a-35S]ATP (sequencing 
grade) and [35S]methionine (translation grade) were ob- 
tained from DuPont (NEN Products, Stevenage, Herts., 
UK) and the Sequenase Version 2.0 DNA sequencing kit 
from USB (United States Biochemical, distributed by 
Amersham Life Science). Sulfosuccinimidyl-4-(N-malei- 
midomethyl)cyclohexane- 1-carboxylate (Sulfo-SMCC), 
SulfoLink coupling gel, and Immunopure gentle Ag/Ab 
elution buffer were obtained from Pierce, Chester, UK. 
The C-terminal peptide was synthesised by Zinsser Ana- 
lytic, Maidenhead, UK, and Keyhole limpet haemocyanin 
(KLH) was supplied by Calbiochem, Nottingham, UK. 
Purified N-glycanase F and BzNLT (N-benzoyl-Asn-Leu- 
Thr-N-methylamide) were generous gifts of Prof. M.J.A. 
Tanner of this department. CHO MCT1 (77499) was ob- 
tained from the American Type Culture Collection (Mary- 
land, USA). Reagents used for immunoblotting, such as 
the ECL (enhanced chemiluminescence) d tection kits were 
obtained from the sources given previously [4]. 
2.2. Methods 
2.2.1. Cloning and sequencing of MCT1 from Ehrlich 
Lettr£ tumour cells 
Ehrlich Lettr6 tumour cells were cultured and harvested 
as described previously [6] and total cell RNA isolated 
using TRizol Reagent, according to the manufacturers' 
instructions, cDNA was prepared from the polyadenylated 
mRNA by reverse transcription and subjected to PCR 
using Taq polymerase. The primers used corresponded to
the initiator methionine codon and last 27 bases of the 5' 
noncoding region of CHO MCT1 (i) and the complemen- 
tary 3' terminal sequence corresponding to the stop codon 
and first 27 bases of the 3' noncoding region (ii): (i) 
5'-GCATTTTGGGATTCATCTACACTTAAAATG-3' (ii) 
5'-CACACAATGCTCTATTCATGCTTCAGTTCA-3'. 
PCR amplification used a 7 min hot start at 94°C, with 
35 cycles of 60 s at 55°C, 90 s at 72°C and 60 s at 94°C. 
The resulting PCR product, which was visible as a 1.5 kb 
fragment on agarose gel electrophoresis, was purified us- 
ing a QIAquick spin column. The cDNA fragment was 
then ligated into SmaI-digested pUC18 vector treated with 
bacteria alkaline phosphatase. Both strands of one clone 
and the sense strand of two further clones (one with a 
truncated version of the full length cDNA), each derived 
from independent cDNA preparations and PCR, were se- 
quenced manually or on a DuPont Genesis 2000 automated 
sequencer using the Sanger dideoxy method of chain ter- 
mination and a custom primer walking strategy. 
2.2.2. Anti-MCT-1 antibodies 
A peptide corresponding to residues 478-494 of CHO 
MCTI, with the addition of an N-terminal Cys residue to 
enable coupling; i.e., CPQQNSSGDPAEEESPV, was used 
to raise antibodies in New Zealand White rabbits. The 
peptide was injected as a Keyhole Limpet Haemocyanin 
conjugate, which was prepared using the water-soluble 
heterobifunctional crosslinker sulfo-SMCC. IgG was ob- 
tained from the serum using caprylic acid [7]. The specific 
antipeptide antibodies were prepared from this IgG frac- 
tion by affinity purification using a peptide column. This 
affinity matrix was synthesised by linking the peptide (via 
the terminal Cys) to Sulfolink coupling gel (Pierce), ac- 
cording to the manufacturers' instructions. The coupling 
ratio for the reaction was 1 mg peptide/ml Sepharose. 
Antibody which bound to this column was eluted with 
Pierce 'gentle Ab/Ag elution buffer', the buffer ex- 
changed to 20 mM Mops, 150 mM NaCI, pH 7.4 and 
purified antibody stored at -70°C. 
2.2.3. Studies of the glycosylation status of MCT1 
Plasma membranes from mouse or Chinese hamster 
erythrocytes, and from CHO cells and mouse Ehrlich-Let- 
tr6 tumour cells were prepared by hypotonic lysis of the 
cells in 5 mM sodium phosphate (pH 8.0) containing the 
protease inhibitor phenylmethanesulfonyl fluoride (PMSF) 
at 2 mM [4]. CHO cells were initially removed from the 
culture dishes by scraping whilst the mouse Ehrlich-Lettr~ 
tumour cells were disrupted by passage through a narrow 
bore needle (0.5 × 16 mm, 25G) up to 10 times. Approx. 
50 /_Lg of membrane protein was then incubated in 25 /xl 
of PBS buffer before addition of SDS (0.5% final) fol- 
lowed by NP40 (0.6% v /v  final) and mercaptoetbanol (8 
mM final). A proteinase inhibitor cocktail (100 /xM leu- 
peptin, 2 /xg/ml aprotinin, 1 mM benzamidine, 1 /xM 
pepstatin and 0.5 mM PMSF; final concentrations) was 
also added to each assay, and the final volume brought o 
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1 ATGCCACCTGCGA~CAGTGGGATAC~C CCCCCCAGATGGAGC~ TGTTAGTC ~%~CC TTCATTTC TATT  
M P P A I G G P V G Y T P P D G G W G W A V L V G A F I S I 30 
* 
91 GGC TTC TC C TATGCATTTCCCAAATCCATCAC TGTCTTC T TTA .CGACCAGTC~kAGTATCATGG 
G F S Y A F P K S I T V F F K E I E V I F $ A T T S E V S W 60 
181 ATATCATCTATAATGTTGGC TGTCATGTATGC TGGAGGTCC TATCAGC2kGTATC TTG~8~AA.TAAA~ GGCAGC C GTCCAGT/~k~ 
I S S I M L A V M Y A G G P I S S I L V N K Y G S R P V M I 90 
271 GC TGGTGGTTGTC TGTC TGGTTGCGGC TTGATCGCAC-C TTC TTTC TGTAACACAG~_C TTTAC TTGTGCATTGGTGTTATTGGA 
A G G C L S G C G L I A A S F C N T V Q E L Y L C I G V I G 120 
361 GGTC ~ T T G C  TT  TCAAC TTGAACCCAGC TCTGAC TATGATTGGCAAGTATTTC ~ G A C  C2LCTGGC ~ ~ ~ C  
G L G L A F N L N P A L T M I G K Y F Y K K R P L A N G L A 150 
451 A~CCTGTGTTCCTCTCTACCCTGGCTCCACTTAA~TTTCTTTGATATTTTTC~P~~ TTCC TAATT 
M A G S P V F L S T L A P L N Q A F F D I F D W R G S F L I 180 
541 C TTGGGGGCCTCC TCC T .AAATTGTTGTGTAGC TGGATC C C TGATGAGACCAA~C ~ T C A A G C  TAGAAAAAC TCAAGTCC 
L G G L L L N C C V A G S L M R P I G P E 0 V K L E K L K S 210 
631 AAAGAATC TC TACAGGAAGC TGGAAAATCTGATGCAAATACAGATC T C A ~ T C  C ~  TGTCCGTC TTC CAA 
K E S L Q E A G K S D A N T D L I G G S P K G E K L S V F Q 240 
721 ACAA~TTCCTGG~C TTGTC GC TGTTTAC C C A ~  TTTTTAC TGTICC TGTC TC~gA~kTGTGGTCATGTTTTTTGGAC TC 
T I N K F L D L $ L F T H R G F L L Y L S G N V V M F F G L 270 
811 TTTACCCCTTTGGTCTTTCTTAGTAGTTATGG~TAAGGATTTTTCCAG~TCAGCCTTCCTTCTTTCCATTTTGGCTTTT 
F T P L V F L S S Y G K S K D F S S E K S A F L L S I L A F 300 
901 GTTGATATGGTAGCCAGACCGTCCATGGGAC T TGCAG~ CAACACCAAGTGGATC2~F.~E C TCGGATC C2~TAC TTTTTTGC ~ T~ ~T T 
V D M V A R P S M G L A & N T K W I R P R I Q Y F F A A S V 330 
991 GTTGCAAATC~gAGTGTGCCATTTGC TTGCCC C TTTGTC TACAACC TAC GTTGGGTTC TGTGTC TAC G C C ~  ~ ~ C  TTT  
V A N G V C H L L A P L S T T Y V G F C V Y A G V F G F A F 360 
1081 GGTTGGC TCAGC TC TGTATTATTTC-J~AACATTGATC~.~ACC TCATTGGACCCC~TTC TC CAGTGC TGTGGGC TTGGTGAC CATTGTG 
G W L S S V L F E T L M D L I G P Q R F S S A V G L V T I V 390 
1171 GAATGC TGCCCTGTC C TCC TAGGGC CACCAC TTTT.AGGC CGC C TCAATGACATGT.ATGGAGAC TACAA~TACACGTAC TGGGC TTG~ 
E C C P V L L G P P L L G R L N D M Y G D Y K Y T Y W A C G 420 
1261 GTGATCC TCATCATC GCGGGTATC TATC TCTTCATTGGCATGGGCATCAAC TATC ~C TTC T T G C ~ G G A G G A G A A G  
V I L I I /% G I Y L F I G M G I N Y R L L A K E Q K A E E K 450 
1351 ~ C A G C A C C G A T G T C G A C  GAGAAGC ~ G A T C ~ A J ~ S C  TGCACAGTCGCCGCAGCAG 
0 K R E G K E D E A S T D V D E K P K E T M K A A Q S P Q Q 480 
1441 CACAGC TC CGGGGACCCCACAGAGGAGGAGAGCCC TGTC 1479 
H S S G D P T E E E S P V 493 
Fig. 1. Nucleotide and deduced amino acid sequences of mouse Ehrlich-Lettr~ tumour cell MCT1 cDNA. MCT from mouse Ehrlich-Lettr~ tumour cells 
was cloned after PCR amplification and sequenced by the Sanger method of dideoxy mediated chain termination, as described in Section 2.2. Numbers on 
the left refer to nucleotides, whilst those on the right refer to the amino acids. The underlined regions of the protein sequence denote the predicted 
transmembrane regions, assigned on the basis of hydrophobicity using the Kyte and Doolittle algorithm [26]. The asterisk denotes the amino acid 
substitution of Ser 52 in mouse MCTI in place of Asn 52 in CHO MCTI. This leads to the loss of the putative consensus sequence for glycosylation. 
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50 p,i. Where required, N-glycanase-F (20 Oxford Gly- 
cosystems units total), was added and samples incubated at 
37°C for 4 h. Samples containing about 5 /,g of protein 
were analysed by SDS-PAGE and Western blotting with 
the anti-MCTl antibody using ECL for detection of im- 
munoreactive bands. 
In order to investigate the possibility of putative glyco- 
sylation sites being used in MCT1, an in vitro translation 
system was used in the presence and absence of dog 
pancreatic microsomes and the competitive inhibitor of 
core glycosylation, BzNLT (a tripeptide glycosylation ac- 
ceptor) as described by Groves and Tanner [8]. eDNA 
encoding either mouse Ehflich-Lettr~ tumour cell or CHO 
MCT1 was subcloned into KS Bluescript, and expressed in
a cell free rabbit reticulocyte lysate by coupling transcrip- 
tion to translation with T7 RNA polymerase. The assay 
was performed with 0.25 /xg eDNA in a total of 12.5 /,1 
lysate buffer containing [3SS]methionine (0.4 mM, 5 /,Ci 
per assay) in the presence or absence of dog pancreatic 
microsomes (1.25 /.tl per reaction) and 30 p,M BzNLT [8]. 
The translation reaction was incubated for 90 rain at 30°C 
and subsequently, in some cases, for 4 h at 37°C in the 
presence or absence of N-glycanase F (10 Oxford Gly- 
cosystems units total), with the methods as above. BSXG1, 
a plasmid vector with eDNA encoding for Band 3, a 
known membrane glycoprotein, was employed as a posi- 
tive control in these experiments [8]. The in vitro transla- 
tion products were separated by SDS-PAGE and detected 
by either autoradiograph, or fluorography essentially as 
described by Bonner and Laskey [9]. 
3. Results 
3.1. Cloning and sequencing of MCTI .from mouse Ehrlich 
Lettrd tumour cells 
In Fig. l we show the nucleotide sequence and derived 
amino acid sequence of the PCR product amplified using 
the primers derived from the 5' and 3' non-coding regions 
of the published sequence of CHO MCTI. Three separate 
clones derived from separate DNA preparations and PCR 
were used to confirm the final sequence. An alignment of 
the mouse tumour cell MCT1 protein sequence with those 
of Chinese hamster and human MCT1 is shown in Fig. 2. 
The mouse MCT1 sequence is 93% identical with that 
from CHO cells, the differences being mainly conservative 
substitutions occurring primarily in putative loops and the 
C-terminal domain as was noted for human MCT1 [10], 
with which the mouse MCT1 shows 87% identity. Com- 
paring mouse with Chinese hamster MCT1, the mouse 
protein has a single deletion in the C-terminal domain. Of 
greater possible significance is the loss of a consensus ite 
for N-glycosylation site on the first putative extracellular 
loop (Asn52Ser). This consensus ite for glycosylation is 
also absent in human MCT1 [10]. 
3.2. Studies on the glycosylation state of MCT1 
In order to assess the significance of the loss of the 
consensus equence for N-linked glycosylation it was nec- 
essary to establish whether this site was used in CHO 
I MPPAIGGPVGYTPPDGGWGWAVIVGAFISIGFSYAFPKSITVFFKEIE~IFmATTSEVSWISSIMLAVMYAGGPI Mouse 
I MPPAIGGPVGYTPPDGGWGWAVVVGAFISIGFSYAFPKSITVFFKEIEGIFIATTSEVSWISSIMLAVMYAGGPI CHO 
I MPPAIGGPVGYTPPDGGWGWAVVOGAFISIGFSYAFPKSITVFFKEIEGIFmATTSEVSWlSSIMLAVMYIGGPI Human 
76 SSILVNKYGSRPVMIAGGCLSGCGLIAASFCNTVOELYLCIGVIGGLGLAFNLNPALTMIGKYFYKKRPLANGLA Mouse 
76 SSIILVNKYGSRPVMIAGGCLSGCGLIAASFCNTVaELYLCIGVIGGLGLAFNLNPALTMIGKYFYKKRPLANGLA CHO 
76 SSILVNKYGSROVMIIGGCLSGCGLIAASFCNTVQILYICIGVIGGLGLAFNLNPALTMIGKYFYK~RPLANGLA Human 
151MAGSPVFLSTLAPLNQAFFIIFIWRGSFLILGGLLLNCCVAGSLMRPIGP~KIEKLKSKESLQEAGKS ..... Mouse 
151 MAGSPVFLSTLAPLNQAFFGIFGWRGSFLILGGLLLNCCVAGSLMRPIGPKPIKIEKLKSKESLQEAGKS ..... CHO 
151MAGSPVFL~TLAPLNOmFFGIFGWRGSFLILGGLLLNCCVAGILMRPIGPKPIK[]KIKSKISLIIIAGK ~ Humon 
221 --DANTDLIGGSPKGEKISVFOTINKFLDLSLFTHRGFLLYLSGNVVMFFGLFTPLVFLSSYGKaSSEKSAF Mouse 
221 --~ANTDLIGGSPKGEKRSVIQTINKFLDLSLFIHRGFLLYLSGNVVMFFGLFTPLVFLSIYGKSOHYSSEKSAF CHO 
226 IMDANTDLIGIIPKIEKRSVFOTINmFLDLOLFTHRGFLLYLSGNVOMFFGLFIPLVFLSSYGKSOHYSSEKSAF Humon 
29q LLSlLAFVDMVARPSMGLAANTKWIRPRIQYFFAASVVANGVCHLLAPLSTTYVGFCVYAGVFGFAFGWLSSVLF Mouse 
29q LLSILAFVDMVARPSMGLAANTKWIRPRIOYFFAASVVANGVCHLLAPLST~YIGFC~YAGVFGFAFGWLSSVLF CHO 
301LLSILAFVDMVARPSMGLIANTKIIRPRIQYFFAASVVANGVCHILAPLSTTYVGFCVYAGIFGFAFGWLSSVLF Humon 
369 ETLMDLmGPORFSSAVGLVTIVECCPVLLGPPLLGRLNDMYGDYKYTYWACGVlLIIAGIYLFIGMGINYRLLAK Mouse 
36g ETLMDLVGPORFSSAVGLVTIVECCPVLLGPPLLGRLNDMYGDYKYTYWACGVILIIAGIYLFIGMGINYRLIAK CHO 
876 ETLMDLVGPORFSSAVGLVTIVECCPVLLGPPLLGRLNDMYGDYKYTYWACGVILII~GIYLFIGMGINYRLLAK Humon 
4qq EOKAEEKQKLEGKEDE~STDVDEKPKEIKAJSP-QOISSGDPIEEESPV. Mouse 
qqq EOKAEEKaKIHIEGKEDITSTDVDEKPKEmTKAIIESP-OOISSGDPmEEESPV C.O 
q51EOKAIEI~K--EIKE~I'ETSODVDImKPIEOTKI-AESPI~GIPIEEESPV Human 
Fig. 2. Alignment of the protein sequences of MCTI ~om mouse Ehrlich-Lettr~ tumour cells with Chinese hamster and human MCTI. The deduced 
pro~in sequence of mouse Ehrlich-Lett~ tumour cell MCTI is aligned against hat ~r  Chinese hamster and human MCT1 taken ~om published ata 
[2,10]. Alignments were performed using Meg~ign so~w~e (DNAStar) with the Clustal algorithm (gap penalty = 10, gap length penalty = 10). Residues 
which are nm identical in all thee sequences ~e highlighted. The deduced amino acid sequence of mouse MCT1 has 93% identity to CHO MCTI and 
87% identity to human MCT1. 
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a) Chinese Hamster 
CHO cell RBC 
N-glycanase F ~-- + 
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97- -  
58 - -  
40 - -  
29 m 
b) 
+ 
97- -  
58 - -  
40 - -  
29 - -  
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Lettr~ cells RBC 
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Fig. 3. N-Glycanase-F treatment of MCT1 in membrane preparations 
from Chinese hamster and mouse cells. Membranes were prepared from 
CHO cells, mouse Ehrlich-Lettr6 tumour cells (Lettr~ cells) and red blood 
cells (RBC) from Chinese hamster or mouse, and treated with N- 
glycanase-F as described in Section 2.2. 5/zg of each membrane prepara- 
tion, with (+)  and without ( - )  treatment with N-glycanase F were 
separated by SDS-PAGE and immunoblots probed with an anti-MCTl 
antibody. The ECL developed blots were exposed for 2 min (a) and 10 
min (b). 
MCT1. We have previously noted a difference in the 
mobility of MCT1 from rabbit, rat and guinea pig which 
would be consistent with different glycosylation states [4]. 
However rabbit MCT1, which runs on SDS-PAGE at a 
higher apparent molecular weight than MCTI from other 
species, showed no change in mobility following treatment 
with N-glycanase-F [5]. In Fig. 3 we show that CHO 
MCT1 was also unaffected by N-glycanase F treatment 
under conditions which caused a sharpening and increased 
mobility of human GLUT 1 (data not shown). MCT1 from 
Chinese hamster red blood cell membranes also showed no 
change in mobility under these conditions, although sur- 
prisingly the protein ran at a higher apparent molecular 
weight than CHO MCTI. MCTI from mouse red blood 
cell or Ehrlich Lettr6 tumour cells exhibited identical 
mobility on SDS-PAGE and this was also unaffected by 
N-glycanase F treatment. Thus, our results suggest hat 
MCT1 is not glycosylated in CHO cells despite the pres- 
ence of a potential glycosylation site. However, it is 
possible that the N-glycanase F is sterically prevented 
from removing the carbohydrate moiety, which might be 
present in greater quantity in Chinese hamster ed blood 
cells, thus accounting for its decreased mobility. 
In order to assess more directly whether CHO MCT1 
can be glycosylated we used the coupled rabbit reticu- 
locyte in vitro transcription and translation system, in the 
presence and absence of dog pancreatic microsomes to 
enable glycosylation to occur. Human erythrocyte band 3 
(AEI) cDNA was used as a control since this is known to 
be glycosylated under such conditions in a manner that is 
sensitive to BzNLT, a tripeptide glycosylation acceptor 
that acts as a competitive inhibitor of core glycosylation, 
and that this glycosylation can be reversed by N-glycanase 
F treatment [8]. In Fig. 4a we show that human band 3 
behaved as expected under our conditions. Thus, in the 
a) 
Plasmid 
Microsomes 
BzNLT 
Glycanase F 
BS 133 b3 b3 b3 
+ + + 
+ 
+ 
b) 
Plasmid 
Microsomes 
BzNLT 
Glycanase F 
hMT hMT hMT hMT mMT mMT mMTI mMT 
+ + + + + + 
+ + 
+ + 
Mr (kDa) 
97- -  
58 - -  
40- -  
-4 -  band 3 
Mr (kDa) 
58- -  
40- -  
29- -  
MCT1 
Fig. 4. Cell free translation of MCT1 from Chinese hamster and mouse in the presence and absence of microsomes, BzNLT and N-glycanase-F. A coupled 
rabbit reticulocyte lysate was used for cell free transcription and translation to express human Band 3 (b3) cDNA, or MCTI cDNA (MT) from Chinese 
hamster (hMT) and mouse (mMT) cells, as described in Section 2.2. In all cases, assays contained 0.25 p,g of the relevant cDNA, and where specified, dog 
pancreatic microsomes (1.25 /xl) and BzNLT (30 ~M). Once expression was complete, where indicated, the lysate was also treated with 10 U of 
N-glycanase-F as described in Section 2.2. 1 /zl of each lysate mix (2 /xl for the N-glycanase-F digest) were separated using SDS-PAGE on gels 
containing 8% (band 3) or 10% (MCT1) (w/v)  polyacrylamide. The gel in Fig. 4a was subjected to autoradiography to visualize the 35S-labelled proteins 
whilst the gel in Fig. 4b was subjected to fluorography. Negative control assays in Fig. 4a contained either KS Bluescript vector (BS) or water ( - ) .  
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absence of microsomes, the synthesised protein ran as a 
fairly sharp single band which in the presence of micro- 
somes became a doublet with the higher glycosylated band 
having a slightly lower mobility. When BzNLT was added 
in the presence of the microsomes, the major product was 
the non-glycosylated lower band and this was also seen if 
the product from the microsomal incubation was incubated 
with N-glycanase F. In direct contrast o this, the data of 
Fig. 4b show that when CHO MCTI cDNA was added to 
the assay, a protein with an apparent molecular mass 
identical to MCT1 (40 kDa) was synthesised, but neither 
the presence of microsomes nor the addition of BzNLT or 
N-glycanase F had any effect on its mobility. Taken to- 
gether, our data strongly suggest that the potential N- 
glycosylation site of CHO MCTI is not utilised. 
4. Conclusions 
The data we present in this paper demonstrate that 
mouse Ehrlich Lettr~ tumour cells express MCT1, and 
provide strong support for our previous kinetic data [6] 
which indicated that the properties of the monocarboxylate 
carrier in these cells corresponded almost exactly to those 
of MCT1. We cannot completely rule out that these cells 
contain another MCT isoform in addition to MCT1, but 
this is unlikely in view of the similar kinetic characteristics 
of lactate transport into tumour cells and erythrocytes 
where MCT1 is known to be responsible. Since MCT1 
appears to be the major isoform present in tumour cells, 
erythrocytes and CHO cells, it would seem likely that it is 
the standard 'housekeeping' monocarboxylate carrier for 
those cells whose requirement for lactate transport is purely 
to allow effiux of glycolytically derived lactic acid. In this 
regard it may be the MCT counterpart of GLUT1 which is 
the glucose transporter found in similar cells [11,12]. In 
contrast, liver parenchymal cells that use lactic acid as a 
substrate for gluconeogenesis and lipogenesis have a dis- 
tinct isoform that has recently been cloned and sequenced 
and termed MCT2 [3]. In heart cells, which can both utilise 
lactic acid as a respiratory substrate and produce it gly- 
colytically during hypoxia, both MCT1 and MCT2 can be 
detected by immunofluorescent microscopy, but only at 
low levels and restricted to the intercalated isk region 
([2,3] and X. Wang and R.C. Poole unpublished ata). 
However, our own studies suggest the presence of substan- 
tial activities of two other isoforms of MCT which exhibit 
kinetics and substrate and inhibitor specificities distinct 
from MCT1 and MCT2 [13-16]. These isoforms have yet 
to be cloned and sequenced. It is significant however that 
basal levels of MCT1 do appear to be present in both liver 
and heart cells despite the majority of transport being 
mediated by different isoforms [1]. This is also the case 
with GLUT l which is often present at low levels in cells 
where another isoform dominates [11]. 
The mouse and Chinese hamster MCT1 sequences are 
93% identical with the mouse and human MCT1 se- 
quences being 87% identical. The majority of changes are 
conservative substitutions and in putative loop regions or 
the C-terminal domain. It is a characteristic of membrane 
transporters that hydrophilic portions of the protein are 
more poorly conserved between species and isoforms than 
membrane spanning segments [17]. The species variation 
in the C-terminal sequence also explains why in Western 
blots the sensitivity of detection of MCT1 by our antipep- 
tide antibody (raised to residues 478-494 of CHO MCT1) 
varies depending on the source of the erythrocyte ghosts or 
other membrane preparation used, when transport activities 
are similar. 
The most interesting difference between the mouse and 
Chinese hamster sequence is the lack of an externally 
disposed consensus equence for N-linked glycosylation i
mouse MCT1. This site is also lacking in the human 
MCTI sequence [10]. As expected from the sequence, we 
found no N-linked glycosylation of mouse MCTI. Hence, 
it is clear that MCT1 can be expressed and function 
correctly without glycosylation. This is perhaps not sur- 
prising since N-linked carbohydrate has been removed 
from many transporters either enzymatically or by site-di- 
rected mutagenesis, with little if any effect on function 
(see for example, [18-21]). Whilst the non-glycosylated 
nature of mouse MCTl was fully expected, we were also 
unable to provide any evidence for N-linked glycosylation 
of CHO MCTI, despite the presence of a consensus ite. 
There are a number of possible explanations for this 
observation. Firstly, the consensus acceptor sequence (N- 
X -S /T  where X is not P) at N 52 in CHO MCTI may not 
be externally disposed and hence not available for glyco- 
sylation. Secondly, and perhaps more likely, the size of the 
loop between putative TMI and TM2 may not be suffi- 
ciently large to be an acceptor for N-linked carbohydrate. 
Studies of the in vitro expression of a membrane protein in 
which the glycosylation site was engineered to be at 
increasing distances from the membrane, implied that 
glycosylation only occurs when there are at least 10 
residues on either side of the asparagine acceptor in the 
exposed loop [22,23]. Furthermore, a recent comprehensive 
survey of the occurrence and utilisation of consensus ites 
for N-linked glycosylation i multiple-spanning membrane 
proteins also concluded that the asparagine acceptor must 
be at least 10 residues away from a transmembrane do- 
main, and that a loop of at least 30 residues in length is 
normally required [24]. The only exception to these rules 
was the CHIP28 water channel (loop approx. 20 residues), 
but only approx. 25% of the protein is actually glyco- 
sylated in this case [25]. The estimated size of the loop 
between transmembrane s gments 1 and 2 of MCTI is 
approx. 23 residues, with only 8 residues on the C-terminal 
side of N 52 (see Fig. 1), and hence this asparagine is 
unlikely to be glycosylated. 
It is interesting to note that the vast majority of multi- 
spanning membrane proteins are glycosylated. Indeed, a 
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large proportion of the few which are not glycosylated 
(e.g., c~-subunit of Na/K-ATPase) are known to be tightly 
associated with other, glycosylated, subunits/proteins [24]. 
It is therefore tempting to speculate that MCT1 might be 
associated with another protein in the membrane. 
The one observation that is difficult to explain is the 
higher apparent molecular weight of MCTI in erythrocytes 
from Chinese hamster as compared with CHO cells. This 
is unlikely to be due to N-glycosylation since in Chinese 
hamster erythrocyte ghosts there is no increase in mobility 
or sharpening of the MCT1 band on SDS-PAGE after 
treatment of ghosts with N-glycanase F sufficient to re- 
move carbohydrate from human GLUT 1. There can be 
little doubt that MCT-1 is the isoform expressed in these 
cells since a variety of anti-(MCTl peptide) antibodies 
react with the protein in Chinese hamster erythrocytes 
(R.C. Poole, unpublished work). We have also observed 
that the MCT1 present in rat heart cell plasma membranes 
shows slightly greater mobility on SDS-PAGE than does 
MCT1 in red cell ghosts (X. Wang, unpublished ata). It is 
of note that MCTI expressed in erythrocytes from a 
number of different mammalian species does have differ- 
ent mobility on SDS-PAGE [4]. These differences between 
MCT1 of membranes from different cells and different 
species might be related to some other post-translational 
modification of the protein, as yet unidentified. Although 
consensus equences for a variety of protein kinase phos- 
phorylation sites can be identified in the rat, mouse and 
Chinese hamster MCT1 sequences, we have been unable to 
demonstrate any changes in mobility of MCT1 following 
alkaline phosphatase treatment (unpublished ata of R.C. 
Poole). 
In conclusion, our data indicate that MCTI is the 
lactate/monocarboxylate transporter expressed in mouse 
ascite tumour cells, and presumably other tumour cells. 
Whilst this may appear to make MCT1 a less promising 
target for cancer chemotherapy, this may not be the case. It 
is now clear that the major tissues of lactate production 
and utilisation (white skeletal muscle, liver, heart) utilise 
isoforms other than MCT1 for lactate transport [2,3,15]. 
Those cells/tissues which express MCTI as the major or 
sole isoform, e.g., erythrocytes, may survive even if this 
process is inhibited, whereas turnout cells have a clear 
requirement for high rates of lactate efflux. 
5. Addendum 
We have recently cloned and sequenced MCT1 from a 
rat skeletal muscle cDNA library and shown that it is 96% 
identical to mouse MCTI at the protein level and also 
lacks a consensus glycosylation site [27]. 
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